Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease.
about
Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer diseasePotential Therapeutical Contributions of the Endocannabinoid System towards Aging and Alzheimer's DiseaseThe airbag problem-a potential culprit for bench-to-bedside translational efforts: relevance for Alzheimer's diseaseAlzheimer disease models and human neuropathology: similarities and differencesCurrent neuroimaging techniques in Alzheimer's disease and applications in animal modelsThe amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy.Why pleiotropic interventions are needed for Alzheimer's disease.Role of presenilins in neuronal calcium homeostasismNos2 deletion and human NOS2 replacement in Alzheimer disease modelsPrediction of miRNA-mRNA associations in Alzheimer's disease mice using network topology.Alzheimer's proteins, oxidative stress, and mitochondrial dysfunction interplay in a neuronal model of Alzheimer's disease.Probing the biology of Alzheimer's disease in mice.Aging and cerebrovascular dysfunction: contribution of hypertension, cerebral amyloid angiopathy, and immunotherapyContribution of complement activation pathways to neuropathology differs among mouse models of Alzheimer's disease.NO synthase 2 (NOS2) deletion promotes multiple pathologies in a mouse model of Alzheimer's disease.Cortical iron regulation and inflammatory response in Alzheimer's disease and APPSWE/PS1ΔE9 mice: a histological perspectiveAmyloid deposition and advanced age fails to induce Alzheimer's type progression in a double knock-in mouse modelGRK5 deficiency exaggerates inflammatory changes in TgAPPsw miceRole of Lipids in Brain Injury and Diseases.Regeneration in a degenerating brain: potential of allopregnanolone as a neuroregenerative agent.Altered lipid metabolism in brain injury and disorders.Amyloid plaques in PSAPP mice bind less metal than plaques in human Alzheimer's disease.The effects of NOS2 gene deletion on mice expressing mutated human AbetaPP.Longitudinal study of differential protein expression in an Alzheimer's mouse model lacking inducible nitric oxide synthase.Expression of complement system components during aging and amyloid deposition in APP transgenic mice.Complement-associated deposits in the human retinaTherapeutic potential of vaccines for Alzheimer's disease.Deciphering the mechanism underlying late-onset Alzheimer disease.Should development of Alzheimer's disease-specific intravenous immunoglobulin be considered?Neurotropin® alleviates hippocampal neuron damage through a HIF-1α/MAPK pathway.Amyloid reduction by amyloid-beta vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer's disease.Use of copper and insulin-resistance to accelerate cognitive deficits and synaptic protein loss in a rat Abeta-infusion Alzheimer's disease modelProgression of amyloid pathology to Alzheimer's disease pathology in an amyloid precursor protein transgenic mouse model by removal of nitric oxide synthase 2Presence of severe neuroinflammation does not intensify neurofibrillary degeneration in human brain.Plaque complement activation and cognitive loss in Alzheimer's disease.Endoproteolytic cleavage of FE65 converts the adaptor protein to a potent suppressor of the sAPPalpha pathway in primates.A case for a non-transgenic animal model of Alzheimer's disease.Curcumin-loaded PLGA-PEG nanoparticles conjugated with B6 peptide for potential use in Alzheimer's disease
P2860
Q21144713-1898C669-A92E-4BA0-8FF6-BC7BA634AFD8Q26783325-06AA13A0-D81A-4763-829E-E23764707385Q26991654-0FCB1A95-D591-4BC4-BECF-DB89354B5EF8Q30499574-EF64DA63-F0C9-4CF1-8B59-FAE131889C16Q30576714-A1F8B5F5-7843-4815-BA73-96C63E1ADFABQ30668465-24787E57-D83F-4AA4-AF20-814D05127920Q33876128-F0928FF4-6882-4D6D-81B8-DEFA959A7946Q34003214-C41158AA-0609-498B-B692-0419BD9A77A3Q34041402-D21CC11A-DE4C-47F1-A47D-BDD0D56C7A77Q34045195-1759D17A-C85F-48B3-A25A-151836006390Q34127614-8570969A-5579-4B59-8CBA-0AF5087934CBQ34206962-0CFAF36E-15E1-4C91-8E70-75B41DAC31C5Q34219814-33C25417-F7C6-485E-BA75-569925FE6972Q34550347-402DAFF3-202E-43E3-B3BE-382276CB065BQ34998995-1AED79D3-3650-48AB-A978-F8154968A282Q35880679-24C3D8DC-A7A7-4A4E-914B-F525AE91D69EQ36040886-343E6FA4-1112-4510-A30F-41CC8EF5E2B2Q36740925-0E0A1D3A-9984-4660-9D13-6644F4EE1504Q37051065-7E2F8709-C270-4100-8E8F-15141F2D807FQ37065308-183A1365-C27C-4991-A200-4EE0C559C99CQ37254313-F054401F-AD2C-417D-894E-D35D25261120Q37353039-CC439486-0C12-4912-B700-1A2C6735BE39Q37354744-F810DE59-F08C-4386-8949-0D735B525A27Q37419731-82C63AB8-9BAB-4471-AAB5-662840CDBF67Q37443394-AACB2A0E-1EDB-4880-9908-C7F9FC35F1A4Q37626363-7395B450-A8D7-4E5E-9D5D-26B91939058AQ37842339-959B3A8A-B242-4DEA-918B-F26F8148EF8AQ38062817-90638345-1D12-48EE-B789-6620D2FDD2B7Q38283308-C2745B42-2C06-4F3C-9D91-171293476BDDQ38713184-D1A29877-27AD-46AE-A5F6-EA56D5D75987Q40598120-A9E9DCB1-490F-4246-A768-0B038B7CBEA3Q41951938-8B278004-807D-45CE-B209-31FA689C77C0Q42132981-5EBD5E86-8A33-4125-A9C7-1B53392102D6Q42239439-E9ACB7A3-A8DC-426A-9D66-443020318BB9Q43111970-CB005205-FEF1-457E-B060-C7A4903E77E0Q45221632-C31B0BAA-5F47-43C3-B648-3048A321A7C9Q48943001-4F6A6A5E-6CD0-4981-A48E-C33A77A3D863Q58776704-BC26956D-B2C2-4A6E-84A7-58AF1CC062A8
P2860
Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Transgenic mice overexpressing ...... te model of Alzheimer disease.
@en
Transgenic mice overexpressing ...... te model of Alzheimer disease.
@nl
type
label
Transgenic mice overexpressing ...... te model of Alzheimer disease.
@en
Transgenic mice overexpressing ...... te model of Alzheimer disease.
@nl
prefLabel
Transgenic mice overexpressing ...... te model of Alzheimer disease.
@en
Transgenic mice overexpressing ...... te model of Alzheimer disease.
@nl
P1476
Transgenic mice overexpressing ...... te model of Alzheimer disease.
@en
P2093
Claudia Schwab
Patrick L McGeer
P356
10.1016/J.EXPNEUROL.2004.03.016
P407
P577
2004-07-01T00:00:00Z